Nephrogenic systemic fibrosis: Relationship to gadolinium and response to photopheresis

Archives of Dermatology

Volumn 143, Issue 8, 2007, Pages 1025-1030

  Richmond, Heather ^a   Zwerner, Jeffrey ^a   Kim, Youn ^a   Fiorentino, David ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; DEXAMETHASONE; ETRETIN; GADODIAMIDE; IMMUNOGLOBULIN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PUVA; RANGE OF MOTION; TREATMENT DURATION; VEIN THROMBOSIS;

ADULT; AGED; COHORT STUDIES; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOTOPHERESIS; RETROSPECTIVE STUDIES; SKIN;

EID: 34548081541     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.8.1025     Document Type: Article

References (30)

1. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 2006;8(2):151-157.
2. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial. 2006;19(3):191-194.
3. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol. 2006;54(2)(suppl):S31-S34.
4. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130(2):209-212.
5. Saenz A, Mandal R, Kradin R, Hedley-Whyte ET. Nephrogenic fibrosing dermopathy with involvement of the dura mater. Virchows Arch. 2006;449(3):389-391.
6. Cowper SE. Nephrogenic fibrosing dermopathy. NFD/NSF Web site; 2001-2006. http://www.icnfdr.org. Accessed August 15, 2006.
7. Auron A, Shao L, Warady BA. Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol. 2006;21(9):1307-1311.
8. Scheinfeld N. Nephrogenic fibrosing dermopathy a comprehensive review for the dermatologist. Am J Clin Dermatol. 2006;7(4):237-247.
9. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet. 2000;356(9234):1000-1001.
10. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-790.
11. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145(3):234-235.
12. Cowper SE, Bucala R, Leboit PE. Fibrosing dermopathy/nephrogenic systemic fibrosis - setting the record straight. Semin Arthritis Rheum. 2006;35(4):208-210.
13. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104-1108.
14. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362.
15. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56(1):27-30.
16. Läuchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004;208(3):278-280.
17. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005;152(3):531-536.
18. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25(1):84-88.
19. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathological features of nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2003;48(1):42-47.
20. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48(1):55-60.
21. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114(7):563-572.
22. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903-906.
23. van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost. 2000;26(3):313-324.
24. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999;55(3):1028-1035.
25. Nampoory MR, Das KC, Johny KV, et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis. 2003;42(4):797-805.
26. Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol. 2006;26(1):46-51.
27. US Food and Drug Administration. Public health advisory: update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. http://www.fda.gov/cder/drug/advisory/ gadolinium_agents_20061222.htm. Accessed April 6, 2007.
28. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5(7):491-502.
29. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide [published online ahead of print October 24, 2006]. Eur Radiol. 2006;16(12):2619-2621.
30. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(1):21-26.